Professor Robert Howard (UCL Institute of Mental Health) said: 'The longer [competitor] lecanemab has a licence but donanemab doesn't, the more the available (but limited) US capacity to treat patients with amyloid antibodies will be blocked by the first drug to hit the market.'
Read: Daily Mail; More: Hindustan Times, La Presse (Canada)
Close
